• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本大流行及大流行后期四个季节中分离的耐神经氨酸酶抑制剂的甲型 H1N1pdm09 流感病毒的特征。

Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan.

机构信息

Laboratory of Influenza Virus Surveillance, Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

出版信息

Influenza Other Respir Viruses. 2013 Nov;7(6):1390-9. doi: 10.1111/irv.12132. Epub 2013 Jun 8.

DOI:10.1111/irv.12132
PMID:23745712
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4634248/
Abstract

BACKGROUND/OBJECTIVES: Japan has the highest frequency of neuraminidase (NA) inhibitor use against influenza in the world. Therefore, Japan could be at high risk of the emergence and spread of NA inhibitor-resistant viruses. The aim of this study was to monitor the emergence of NA inhibitor-resistant viruses and the possibility of human-to-human transmission during four influenza seasons in Japan.

METHODS

To monitor antiviral-resistant A(H1N1)pdm09 viruses, we examined viruses isolated in four seasons from the 2008-2009 season through the 2011-2012 season in Japan by allelic discrimination, NA gene sequencing, and NA inhibitor susceptibility.

RESULTS

We found that 157 (1·3%) of 12 026 A(H1N1)pdm09 isolates possessed an H275Y substitution in the NA protein that confers about 400- and 140-fold decreased susceptibility to oseltamivir and peramivir, respectively, compared with 275H wild-type viruses. The detection rate of resistant viruses increased from 1·0% during the pandemic period to 2·0% during the post-pandemic period. The highest detection rate of the resistant viruses was found in patients who were 0-9 years old. Furthermore, among the cases with resistant viruses, the percentage of no known exposure to antiviral drugs increased from 16% during the pandemic period to 44% during the post-pandemic period, implying that suspected human-to-human transmission of the resistant viruses gradually increased in the post-pandemic period.

CONCLUSIONS

A(H1N1)pdm09 viruses resistant to oseltamivir and peramivir were sporadically detected in Japan, but they did not spread throughout the community. No viruses resistant to zanamivir and laninamivir were detected.

摘要

背景/目的:日本是世界上使用神经氨酸酶(NA)抑制剂治疗流感频率最高的国家。因此,日本可能面临着出现和传播 NA 抑制剂耐药病毒的高风险。本研究旨在监测日本四个流感季节中 NA 抑制剂耐药病毒的出现以及人际传播的可能性。

方法

为了监测抗流感病毒药物耐药的 A(H1N1)pdm09 病毒,我们通过等位基因鉴别、NA 基因测序和 NA 抑制剂敏感性试验,检测了日本 2008-2009 年至 2011-2012 年四个季节分离的病毒。

结果

我们发现,与野生型 275H 病毒相比,157 株(1.3%)A(H1N1)pdm09 分离株的 NA 蛋白中存在 H275Y 取代,对奥司他韦和帕拉米韦的敏感性分别降低了约 400 倍和 140 倍。耐药病毒的检出率从大流行期间的 1.0%增加到大流行后期的 2.0%。耐药病毒的最高检出率见于 0-9 岁的患者。此外,在耐药病毒的病例中,无已知抗病毒药物暴露史的比例从大流行期间的 16%增加到大流行后期的 44%,这表明耐药病毒的人际传播在大流行后期逐渐增加。

结论

日本偶有发现对奥司他韦和帕拉米韦耐药的 A(H1N1)pdm09 病毒,但并未在社区中传播。未检测到对扎那米韦和拉尼米韦耐药的病毒。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63cc/4634248/26cc31c80ae3/IRV-7-1390-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63cc/4634248/1ffaba4d4806/IRV-7-1390-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63cc/4634248/12eb4e212890/IRV-7-1390-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63cc/4634248/9b24280cd34b/IRV-7-1390-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63cc/4634248/26cc31c80ae3/IRV-7-1390-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63cc/4634248/1ffaba4d4806/IRV-7-1390-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63cc/4634248/12eb4e212890/IRV-7-1390-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63cc/4634248/9b24280cd34b/IRV-7-1390-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63cc/4634248/26cc31c80ae3/IRV-7-1390-g004.jpg

相似文献

1
Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan.日本大流行及大流行后期四个季节中分离的耐神经氨酸酶抑制剂的甲型 H1N1pdm09 流感病毒的特征。
Influenza Other Respir Viruses. 2013 Nov;7(6):1390-9. doi: 10.1111/irv.12132. Epub 2013 Jun 8.
2
Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.2009-2010 年和 2010-2011 年流感季节日本大流行和季节性流感病毒的神经氨酸酶抑制剂敏感性特征。
Antiviral Res. 2013 Sep;99(3):261-9. doi: 10.1016/j.antiviral.2013.06.003. Epub 2013 Jun 17.
3
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.2013 - 2014年全球人类流感病毒对神经氨酸酶抑制剂敏感性的最新情况
Antiviral Res. 2015 May;117:27-38. doi: 10.1016/j.antiviral.2015.02.003. Epub 2015 Feb 23.
4
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.全球 2015-2016 年人类流感病毒对神经氨酸酶抑制剂的敏感性更新。
Antiviral Res. 2017 Oct;146:12-20. doi: 10.1016/j.antiviral.2017.08.004. Epub 2017 Aug 10.
5
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.2011 年南半球流感季节期间全球流行的流感病毒神经氨酸酶抑制剂敏感性监测。
Influenza Other Respir Viruses. 2013 Sep;7(5):645-58. doi: 10.1111/irv.12113. Epub 2013 Apr 10.
6
Community- and hospital-acquired infections with oseltamivir- and peramivir-resistant influenza A(H1N1)pdm09 viruses during the 2015-2016 season in Japan.2015 - 2016年日本流行季期间,社区获得性和医院获得性感染对奥司他韦和帕拉米韦耐药的甲型H1N1pdm09流感病毒。
Virus Genes. 2017 Feb;53(1):89-94. doi: 10.1007/s11262-016-1396-9. Epub 2016 Oct 6.
7
Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.N1 神经氨酸酶亚型禽源和猪源流感病毒的抗病毒敏感性。
J Virol. 2010 Oct;84(19):9800-9. doi: 10.1128/JVI.00296-10. Epub 2010 Jul 21.
8
Oseltamivir-resistant seasonal A(H1N1) and A(H1N1)pdm09 influenza viruses from the 2007/2008 to 2012/2013 season in Nara Prefecture, Japan.来自日本奈良县2007/2008至2012/2013季节的对奥司他韦耐药的季节性甲型(H1N1)和甲型(H1N1)pdm09流感病毒。
Jpn J Infect Dis. 2014;67(5):385-8. doi: 10.7883/yoken.67.385.
9
Characterization of oseltamivir-resistant influenza A(H1N1)pdm09 viruses in Taiwan in 2009-2011.2009-2011 年台湾地区奥司他韦耐药甲型 H1N1pdm09 流感病毒的特征。
J Med Virol. 2013 Mar;85(3):379-87. doi: 10.1002/jmv.23482. Epub 2012 Dec 21.
10
Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay.通过双重一步 RT-PCR 检测快速区分大流行性流感 A/H1N1 2009 病毒神经氨酸酶基因中的奥司他韦耐药 275Y 和敏感 275H 取代。
J Med Virol. 2011 Jul;83(7):1121-7. doi: 10.1002/jmv.22101.

引用本文的文献

1
Influenza and Aging: Clinical Manifestations, Complications, and Treatment Approaches in Older Adults.流感与衰老:老年人的临床表现、并发症及治疗方法
Drugs Aging. 2025 Jan;42(1):39-55. doi: 10.1007/s40266-024-01169-y. Epub 2025 Jan 7.
2
Molecular dynamics study on the effect of the N1 neuraminidase double mutant G147R/H274Y on oseltamivir sensitivity.N1神经氨酸酶双突变体G147R/H274Y对奥司他韦敏感性影响的分子动力学研究
RSC Adv. 2024 Dec 10;14(52):39017-39026. doi: 10.1039/d4ra07713j. eCollection 2024 Dec 3.
3
Antivirals Targeting the Neuraminidase.

本文引用的文献

1
Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012.世界卫生组织流感抗病毒药物敏感性监测工作组会议——2011年11月于日内瓦及2012年6月于日内瓦
Wkly Epidemiol Rec. 2012 Sep 28;87(39):369-74.
2
Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012.2012 年 8 月,从西班牙返回的荷兰旅行者中出现了抗奥司他韦的甲型 H1N1pdm09 流感病毒。
Euro Surveill. 2012 Sep 6;17(36):20266.
3
Frequency of oseltamivir resistance in Sydney, during the Newcastle outbreak of community transmitted oseltamivir-resistant influenza A(H1N1)pdm09 virus, Australia, June to August 2011.
抗神经氨酸酶药物。
Cold Spring Harb Perspect Med. 2022 Jan 4;12(1):a038455. doi: 10.1101/cshperspect.a038455.
4
Drug resistance in influenza A virus: the epidemiology and management.甲型流感病毒的耐药性:流行病学与管理
Infect Drug Resist. 2017 Apr 20;10:121-134. doi: 10.2147/IDR.S105473. eCollection 2017.
5
Antiviral therapy for respiratory viral infections in immunocompromised patients.免疫功能低下患者呼吸道病毒感染的抗病毒治疗。
Expert Rev Anti Infect Ther. 2017 Apr;15(4):401-415. doi: 10.1080/14787210.2017.1279970. Epub 2017 Jan 16.
6
Peramivir injection in the treatment of acute influenza: a review of the literature.帕拉米韦注射液治疗急性流感:文献综述
Infect Drug Resist. 2016 Aug 22;9:201-14. doi: 10.2147/IDR.S86460. eCollection 2016.
7
Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.非人灵长类动物中出现对神经氨酸酶抑制剂耐药的H7N9甲型流感病毒
Antimicrob Agents Chemother. 2015 Aug;59(8):4962-73. doi: 10.1128/AAC.00793-15. Epub 2015 Jun 8.
8
Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan.2013 - 2014年日本流感季节期间对奥司他韦和帕拉米韦交叉耐药的一大群甲型H1N1pdm09流感病毒的特征分析
Antimicrob Agents Chemother. 2015 May;59(5):2607-17. doi: 10.1128/AAC.04836-14. Epub 2015 Feb 17.
9
Peramivir and laninamivir susceptibility of circulating influenza A and B viruses.循环流感 A 和 B 病毒对帕拉米韦和拉尼米韦的敏感性。
Influenza Other Respir Viruses. 2014 Mar;8(2):135-9. doi: 10.1111/irv.12187.
2011 年 6 月至 8 月,澳大利亚悉尼新寇兰地区爆发社区传播的奥司他韦耐药性甲型 H1N1pdm09 流感病毒期间,奥司他韦耐药性的发生频率。
Euro Surveill. 2012 Jul 5;17(27):20210. doi: 10.2807/ese.17.27.20210-en.
4
Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia.澳大利亚广泛社区聚集性 H275Y 奥司他韦耐药 A(H1N1)pdm09 流感的特征。
J Infect Dis. 2012 Jul 15;206(2):148-57. doi: 10.1093/infdis/jis337. Epub 2012 May 4.
5
Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11.2010-2011 年美国耐奥司他韦的大流行性(H1N1)2009 病毒感染。
Emerg Infect Dis. 2012 Feb;18(2):308-11. doi: 10.3201/eid1802.111466.
6
Amino acid changes in hemagglutinin contribute to the replication of oseltamivir-resistant H1N1 influenza viruses.氨基酸变化导致血凝素对奥司他韦耐药的 H1N1 流感病毒的复制。
J Virol. 2012 Jan;86(1):121-7. doi: 10.1128/JVI.06085-11. Epub 2011 Oct 19.
7
Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay.通过双重一步 RT-PCR 检测快速区分大流行性流感 A/H1N1 2009 病毒神经氨酸酶基因中的奥司他韦耐药 275Y 和敏感 275H 取代。
J Med Virol. 2011 Jul;83(7):1121-7. doi: 10.1002/jmv.22101.
8
MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods.MEGA5:用于最大似然法、进化距离法和最大简约法的分子进化遗传学分析。
Mol Biol Evol. 2011 Oct;28(10):2731-9. doi: 10.1093/molbev/msr121. Epub 2011 May 4.
9
Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010.监测和特征分析 2009-2010 年日本流行的(H1N1)2009 病毒对奥司他韦的耐药情况。
Emerg Infect Dis. 2011 Mar;17(3):470-9. doi: 10.3201/eid1703.101188.
10
Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11.2010/11 年冬季英国奥司他韦耐药性甲型 H1N1 流感病毒的持续出现和流行情况变化。
Euro Surveill. 2011 Feb 3;16(5):19784.